Assessing the impact of a consensus conference on long-term therapy schizophrenia

International Journal of Technology Assessment in Health Care

Volumn 16, Issue 1, 2000, Pages 251-259

  Glikman, Jacques ^a   Pazart, Lionel ^a   Casadebaig, Françoise ^b   Philippe, Alain ^b   Lachaux, Bernard ^c   Kovess, Viviane ^c   Terra, Jean Louis ^a   Durocher, Alain ^a  

^a Agence Natl d'Accreditation d'E   (France)

^b Inst Natl la S et de Rech Med

^c U d'Eval Rech Therapeutiques M ^*  (France)

Author keywords

Consensus development conferences; Guideline adherence; Guidelines; Practice guidelines; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ADULT; AMBULATORY CARE; ARTICLE; FEMALE; HEALTH CARE POLICY; HOSPITAL CARE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; CONSENSUS DEVELOPMENT CONFERENCES; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; SCHIZOPHRENIA;

EID: 0034064393     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462300161215     Document Type: Article

References (24)

1. Agence Nationale pour le Développement de l'Évaluation Médicale. Stratégies thérapeutiques à long terme dans les psychoses schizophréniques. Texte du consensus. Paris: ANDEM, 1994.
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 1997, 154, 1-63.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-III-R, 3rd ed. Washington, DC: American Psychiatry Association, 1987.
4. Audibert, G., Charpentier, C., Savoye, E., et al. Outcome of the use of albumin and colloid plasma substitutes from 1989 to 1993 in a French University Hospital Center (article in French). Annules Françaises d'Anesthésie et de Réanimation, 1995, 14: 517-22.
5. Casadebaig, F., Philippe, A., Guillaud-Bataille, J. M., et al. Schizophrenic patients: Physical health and access to somatic care. European Psychiatry, 1997, 12, 289-93.
6. Comité d'Organisation, Experts, Promoteurs de la Conférence de Consensus. Conférence de Consensus: Texte des Experts. Stratégies thérapeutiques à long terme dans les psychoses schizophréniques. Paris: Editions Frison-Roche, 1994.
7. Durand-Zaleski, I., Bonnet, F., Rochant, H., et al. Usefulness of consensus conferences: The case of albumin. Lancet, 1992, 340, 1388-90.
8. Durocher, A., Carpentier, F., & Dosquet, P. A methodology for consensus conferences. Acta Belgica Gastroenterologica, 1998, 61, 416-21.
9. EUR-ASSESS Project. Subgroup report on dissemination and impact. International Journal of Technology Assessment in Health Care, 1997, 13, 220-86.
10. Ferguson, J. H. NIH consensus conferences: Dissemination and impact. Annals of the New York Academy of Sciences, 1993, 703, 180-99.
11. Ferguson, J. H. The NIH consensus development program. International Journal of Technology Assessment in Health Care, 1996, 12, 460-74.
12. Glikman, J., Pazart, L., Casadebaig, F., et al. Etude de l'impact de la conférence de consensus 'stratégies thérapeutiques à long terme dans les psychoses schizophréniques.' Encéphale, 1999, 25, 558-68.
13. Hunskaar, S., Nannestad, Y. S., Backe, B., & Matheson, I. Direct mailing of consensus recommendations did not alter GPs' knowledge and prescription of oestrogen in menopause. Scandinavian Journal of Primary Health Care, 1996, 14, 203-08.
14. Kanouse, D. E., Winkler, J. D., Kosecoff, J., et al. Changing medical practice through technology assessment: An evaluation of the NIH consensus development program. A Rand Corporation Research Study. Ann Arbor: Health Administration Press, 1989.
15. Kosecoff, J., Kanouse, D. E., Rogers, W. H., et al. Effects of the National Institute of Health consensus development program on physician practice. JAMA, 1987, 258, 2708-13.
16. Kovess, V. The French consensus conference on long-term therapeutic strategies for schizophrenic psychoses. Society of Psychiatry and Psychiatric Epidemiology, 1995, 30, 49-52.
17. Lachaux, B., Ardiet, G., & Adouard, D. L'abord médicamenteux de la prise en charge des pathologies schizophréniques: Vingt ans après. L'Information Psychiatrique, 1997, 10, 991-97.
18. Le Fur, P., & Sermet, C. Les références médicales opposables. Impact sur la prescription pharmaceutique. Report no. 1116. Paris: CREDES, 1996.
19. Lehman, A. F., Steinwachs, D. M., & co-investigators of the PORT Project. At issue: Translating research into practice - The schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophrenia Bulletin, 1998, 24, 1-10.
20. Lomas, J. Words without action? The production, dissemination and impact of consensus recommendations. Annual Review of Public Health, 1991, 12, 41-65.
21. Maisonneuve, H., Cordier, H., Durocher, A., & Matillon, Y. The French clinical guidelines and medical references programme: Development of 48 clinical guidelines for private practice over a period of 18 months. Journal of Evaluation in Clinical Practice, 1997, 3, 3-13.
22. Quemada, N., Parayre, C., & Boisguérin, B. Enquête nationale sur la prise en charge dans les secteurs de la psychiatrie générale. Direction Générale de la Santé, Ministère de la Santé, 1993.
23. Thamer, M., Ray, N. F., Henderson, S. C., et al. Influence of the NIH consensus conference on Helicobacter pylori on physician prescribing among a Medicaid population. Medical Care, 1998, 36, 646-60.
24. Young, A. S., Sullivan, G., Burnam, A., & Brook, R. H. Measuring the quality of outpatient treatment for schizophrenia. Archives of General Psychiatry, 1998, 55, 611-17.